

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>September 10, 2010</u> (use as many sheets as necessary)				Application Number	10/812,298
				Filing Date	March 29, 2004
				First Named Inventor	Matthieu Guitton
				Art Unit	1628
				Examiner Name	Jennifer M. Kim
Sheet	1	of	3	Attorney Docket Number	067802-3000-001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2004/0062819 A1	04-2004	Keith R. Hildebrand	
	AB	6,656,172	12-2003	Keith R. Hildebrand	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AC	DE 10124953 A1	12-12-2002	Marlies Knipper	German	
	AD	WO2002/15907 A1	2-28-2002	Muller-Schwefe	Abstract	
	AE	WO2004/022069 A1	3-18-2004	Puel, et al.		
	AF	WO2004/101072 A1	11-25-2004	De Koninck, et al.		
	AG	WO2005/073237 A	8-11-2005	Cooper		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AH	Ciocon J. O. et al., "Does oxazepam offer relief of tinnitus or alter it to a non-troublesome functional level in the elderly?" <i>J. of the American Geriatrics Society</i> 45(9):122, Abstract, 1997.	
	AI	Eggermont Jos. J. et al., "The neuroscience of tinnitus," <i>Trends in Neurosciences</i> 27(11): 676-682, 2004.	
	AJ	Menkes David B. et al., "Sodium valproate for tinnitus," <i>J. of Neurology Neurosurgery and Psychiatry</i> 65(5): 803, 1998.	
	AK	Szczepaniak William S. et al., "Effect of L-baclofen and D-baclofen on the auditory system: A study of click-evoked potentials from the inferior colliculus in the rat," <i>Annals of Otolaryngology and Rhinology</i> 104(5): 399-404, 1995.	
	AL	Theopold H.M. et al., "[Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear?]," <i>Laryngologie, Rhinologie, Otolologie</i> 64(12): 609-613, 1985.	
	AM	Vichitrananda C. et al., "Midazolam for the treatment of phantom limb pain exacerbation: preliminary reports," <i>J. of the Medical Associate of Thailand = Chotmaihet Thangphaet</i> 84(2): 299-302.	
	AN	Weber W.E., "[Pharmacotherapy for neuropathic pain caused by injury to the afferent nerve fibers]," <i>Nederlands Tijdschrift voor Geneeskunde</i> 145(17): 813-817, Abstract, 2001.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>September 10, 2010</u> (use as many sheets as necessary)				Application Number	10/812,298
				Filing Date	March 29, 2004
				First Named Inventor	Matthieu Guitton
				Art Unit	1628
				Examiner Name	Jennifer M. Kim
Sheet	2	of	3	Attorney Docket Number	067802-3000-001

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	AO	Bauer, C.A. et al., "A behavioral model of chronic Tinnitus in rats," <i>Otolaryngol. Head Neck Surg.</i> 121:457-462, 1999.		
	AP	Binder, D.K., "The role of BDNF in epilepsy other diseases of the mature nervous system," <i>Recent Advances in Epilepsy Research</i> 34-56, 2004.		
	AQ	Gabellini, N., "Transcriptional regulation by cAMP and Ca ⁺⁺ links the Na ⁺ /Ca ⁺⁺ exchanger 3 to memory and sensory pathways," <i>Mol. Neurobiol.</i> 30:91-116, 2004.		
	AR	Guitton, M.J. et al., "Salicylate induces tinnitus through activation of cochlear NMDA receptors," <i>J. Neurosci.</i> 23:3944-3952, 2003.		
	AS	Ito et al., "A new method for drug application to the inner ear," <i>J. Otorhinolaryngol. Relat. Spec.</i> 272-275, 2005.		
	AT	Knipper, M. et al., "Thyroid hormone deficiency before the onset of hearing causes irreversible damage to peripheral and central auditory systems," <i>J. Neurophysiol.</i> 83:3101-3112, 2000.		
	AU	Kumagai, "Effect of intravenous injection of aspirin on the cochlea," <i>Hokkaido Igaku Tasshi</i> 67(2):216-233, 1992.		
	AV	Lang et al., "Association of BDNF serum concentrations with central sero-tonergic activity: Evidence from auditory signal processing," <i>Neuropsychopharmacology</i> 30(6):1148-1153, 2005.		
	AW	Lehner, R. et al., "A new implantable drug delivery system for local therapy of the middle and inner ear," <i>Ear, Nose Throat</i> 76:567-570, 1996.		
	AX	Middleton, C., "The causes and treatments of phantom limb pain," <i>Nurs. Times</i> 99:30-33, 2003.		
	AY	Schimmang, T. et al., "Lack of BDNF and trkB signaling in the postnatal cochlea leads to a spatial reshaping of innervation along the tonotopic axis and hearing loss," <i>Development</i> 130:4741-4750, 2003.		
	AZ	Stypulkowski, "Mechanisms of salicylate ototoxicity," <i>Hear Res.</i> 46(1-2):113-145.		
	BA	Timmusk, T. et al., "Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice," <i>J. Cell. Biol.</i> 128:185-199, 1995.		
	BB	Waddell, A., Canter, R., "Tinnitus, Am. Fam. Physician 69," 591-592, 2004.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>September 10, 2010</u> <i>(use as many sheets as necessary)</i>				Application Number	10/812,298
				Filing Date	March 29, 2004
				First Named Inventor	Matthieu Guitton
				Art Unit	1628
				Examiner Name	Jennifer M. Kim
Sheet	3	of	3	Attorney Docket Number	067802-3000-001

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	BC	Wang et al., "Evaluating effects of some medicine on tinnitus with animal behavioral model in rats," <i>Zhonghua Er. Bi. Yan. Hou. Ke. Za. Zhi.</i> 35(5): abstract, 2000.		
	BD	West et al., "Calcium Regulation of Neuronal Gene Expression," <i>Proc. Natl. Acad. Sci. USA</i> 98:11024-11031, 2001.		
	BE	Wiechers, B. et al., "A changing pattern of brain-derived neurotrophic factor expression correlates with the rearrangement of fibers during cochlea development of rats and mice," <i>J. Neurosci.</i> 19:3033-3042, 1999.		
	BF	Maier C. et al., "Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial," <i>Pain</i> 103:277-283, 2003.		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.